Skip to main content

Table 2 Serum concentrations of vascular markers in patients with systemic sclerosis (SSc) at baseline and in controls

From: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1

Serum constituent

Controls (n = 20)

SSc patients at baseline (n = 40)

P (Mann–Whitney test)

sVCAM-1 (pg/ml)

465.5 (378–619)

712 (362–1034)

P < 0.0001

Carbonyl residues (nmol/mg protein)

0.34 (0.15–0.64)

0.83 (0.37–1.48)

P < 0.0001

AOPP (μmol/l of chloramine-T equivalents)

75.5 (21–91)

109.1 (50–281)

P < 0.0001

VEGF (pg/ml)

221 (19–499)

573.5 (26–1915)

P = 0.0001

sVEGFR-1 (pg/ml)

19 (8–73)

45 (10–1140)

P = 0.0025

  1. Values are median (range) of serum concentrations in patients or controls. AOPP, advanced oxidation protein products; sVCAM-1, soluble vascular cell adhesion molecule 1; sVEGFR-1, soluble VEGF receptor 1; VEGF, vascular endothelial growth factor.